Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Capivasertib
Cat. No.:
OB0225LY-0278
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Capivasertib is a novel AKT inhibitor that inhibits Akt1, Akt2, and Akt3.
Synonym:
AZD5363; 1143532-39-1; 4-Amino-N-[(1S)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)piperidine-4-Carboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-
CAS No.:
1143532-39-1
Compound CID:
25227436
Formula:
C21H25ClN6O2
Formula Weight:
428.92
Specification
Relative Density:
1.381 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Capivasertib can be used in cancer biology research or play an important role in antitumor drug screening.
Library Information
Targets:
PI3K/Akt/mTOR pathway
Receptors:
Akt1; Akt2; Akt3; Autophagy; mTOR (p70S6K); PKA
Pathways:
Tyrosine kinase/adaptors; Cytoskeletal signaling; Autophagy; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-4
Plate Location:
e7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 116.57 mM
Ethanol Max Solubility:
1 mg/mL
Solubility:
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 8 mg/mL (18.65 mM), insoluble in water.
ALogP:
1.317
HBA_Count:
3
HBD_Count:
4
Rotatable Bond:
6
